Trial Outcomes & Findings for A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin (NCT NCT06716645)

NCT ID: NCT06716645

Last Updated: 2026-02-20

Results Overview

The WURSS was an evaluative illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. Participants rated their cold symptoms (10 questions) and Quality of Life (QoL) related 9 questions using WURSS-21. The responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptoms/Not at all and 7=Severe symptoms/Severely. Thus, the minimum and maximum possible total scores were 0 and 133 respectively, where higher total scores indicated more negative impact on symptoms and quality of life. Change from Baseline was calculated as each post-Baseline value minus Baseline value. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

244 participants

Primary outcome timeframe

Baseline and up to Day 7 or End of Treatment (EOT)

Results posted on

2026-02-20

Participant Flow

This study was conducted at a single center in United States of America.

A total of 244 participants were enrolled and randomized to two treatment groups: 122 to Group 1 (Daytime) and 122 to Group 2 (Daytime + Nighttime). A total of 110 participants from the Daytime group and 109 participants from the Daytime + Nighttime group completed the study.

Participant milestones

Participant milestones
Measure
Robitussin Cough Syrup (Daytime)
Participants were instructed to take up to 20 milliliters (ml) of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Overall Study
STARTED
122
122
Overall Study
COMPLETED
110
109
Overall Study
NOT COMPLETED
12
13

Reasons for withdrawal

Reasons for withdrawal
Measure
Robitussin Cough Syrup (Daytime)
Participants were instructed to take up to 20 milliliters (ml) of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Overall Study
Unable to deliver study product
4
7
Overall Study
Lost to Follow-up
6
2
Overall Study
Ineligibility
2
2
Overall Study
Non-compliance
0
2

Baseline Characteristics

A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Robitussin Cough Syrup (Daytime)
n=115 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=112 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Total
n=227 Participants
Total of all reporting groups
Age, Continuous
40.7 years
STANDARD_DEVIATION 11.4 • n=14 Participants
39.4 years
STANDARD_DEVIATION 11.2 • n=14 Participants
40.1 years
STANDARD_DEVIATION 11.3 • n=29 Participants
Sex: Female, Male
Female
73 Participants
n=14 Participants
71 Participants
n=14 Participants
144 Participants
n=29 Participants
Sex: Female, Male
Male
42 Participants
n=14 Participants
41 Participants
n=14 Participants
83 Participants
n=29 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
13 Participants
n=14 Participants
12 Participants
n=14 Participants
25 Participants
n=29 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
102 Participants
n=14 Participants
99 Participants
n=14 Participants
201 Participants
n=29 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=14 Participants
1 Participants
n=14 Participants
1 Participants
n=29 Participants
Race/Ethnicity, Customized
Asian
8 Participants
n=14 Participants
5 Participants
n=14 Participants
13 Participants
n=29 Participants
Race/Ethnicity, Customized
Black or African American
23 Participants
n=14 Participants
28 Participants
n=14 Participants
51 Participants
n=29 Participants
Race/Ethnicity, Customized
Hispanic
1 Participants
n=14 Participants
2 Participants
n=14 Participants
3 Participants
n=29 Participants
Race/Ethnicity, Customized
Latino
1 Participants
n=14 Participants
0 Participants
n=14 Participants
1 Participants
n=29 Participants
Race/Ethnicity, Customized
Middle Eastern
0 Participants
n=14 Participants
1 Participants
n=14 Participants
1 Participants
n=29 Participants
Race/Ethnicity, Customized
Mixed
1 Participants
n=14 Participants
1 Participants
n=14 Participants
2 Participants
n=29 Participants
Race/Ethnicity, Customized
Multiple
6 Participants
n=14 Participants
7 Participants
n=14 Participants
13 Participants
n=29 Participants
Race/Ethnicity, Customized
Native Hawaiian / Other Pacific Islander
1 Participants
n=14 Participants
0 Participants
n=14 Participants
1 Participants
n=29 Participants
Race/Ethnicity, Customized
White
74 Participants
n=14 Participants
67 Participants
n=14 Participants
141 Participants
n=29 Participants
Race/Ethnicity, Customized
Missing
0 Participants
n=14 Participants
1 Participants
n=14 Participants
1 Participants
n=29 Participants

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or End of Treatment (EOT)

Population: The modified Intent-To-Treat (mITT) population included all participants who used study product at least once and had data from at least one post baseline QoL questionnaire to support at least one of the primary endpoint assessments. Only those participants with data available at the specified timepoint were analyzed.

The WURSS was an evaluative illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. Participants rated their cold symptoms (10 questions) and Quality of Life (QoL) related 9 questions using WURSS-21. The responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptoms/Not at all and 7=Severe symptoms/Severely. Thus, the minimum and maximum possible total scores were 0 and 133 respectively, where higher total scores indicated more negative impact on symptoms and quality of life. Change from Baseline was calculated as each post-Baseline value minus Baseline value. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 1
-9.56 score on a scale
Interval -14.45 to -4.66
-9.11 score on a scale
Interval -13.49 to -4.73
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 2
-26.49 score on a scale
Interval -31.51 to -21.47
-22.97 score on a scale
Interval -27.43 to -18.51
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 3
-40.99 score on a scale
Interval -46.09 to -35.89
-36.71 score on a scale
Interval -41.28 to -32.14
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 4
-47.63 score on a scale
Interval -53.07 to -42.18
-47.20 score on a scale
Interval -52.0 to -42.4
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 5
-51.20 score on a scale
Interval -57.14 to -45.25
-55.05 score on a scale
Interval -60.13 to -49.96
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 6
-58.29 score on a scale
Interval -64.83 to -51.75
-64.12 score on a scale
Interval -69.53 to -58.72
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Day 7
-61.58 score on a scale
Interval -69.87 to -53.3
-64.69 score on a scale
Interval -72.62 to -56.76
Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
EOT
-55.64 score on a scale
Interval -60.25 to -51.03
-53.62 score on a scale
Interval -57.7 to -49.55

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The symptom domain of WURSS-21 consisted of 10 questions. Participants rated their cold symptoms related questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptoms and 7=Severe. Thus, the minimum and maximum possible total score was 0 and 70 respectively, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 1
-6.48 score on a scale
Interval -9.0 to -3.95
-5.89 score on a scale
Interval -8.27 to -3.51
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 2
-14.59 score on a scale
Interval -17.18 to -12.0
-13.58 score on a scale
Interval -15.99 to -11.16
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 3
-22.56 score on a scale
Interval -25.19 to -19.93
-21.26 score on a scale
Interval -23.73 to -18.79
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 4
-25.97 score on a scale
Interval -28.79 to -23.16
-26.58 score on a scale
Interval -29.16 to -24.0
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 5
-28.05 score on a scale
Interval -31.13 to -24.98
-30.46 score on a scale
Interval -33.19 to -27.74
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 6
-31.76 score on a scale
Interval -35.15 to -28.37
-35.40 score on a scale
Interval -38.28 to -32.52
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
Day 7
-32.41 score on a scale
Interval -36.72 to -28.11
-37.07 score on a scale
Interval -41.21 to -32.93
Adjusted Mean Change From Baseline in WURSS-21 Total Symptom Domain Score
EOT
-30.03 score on a scale
Interval -32.4 to -27.66
-30.14 score on a scale
Interval -32.34 to -27.95

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated their QoL related questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 63 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 1
-3.06 score on a scale
Interval -5.71 to -0.4
-3.28 score on a scale
Interval -5.73 to -0.83
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 2
-11.87 score on a scale
Interval -14.59 to -9.16
-9.44 score on a scale
Interval -11.94 to -6.93
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 3
-18.40 score on a scale
Interval -21.16 to -15.63
-15.49 score on a scale
Interval -18.07 to -12.91
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 4
-21.56 score on a scale
Interval -24.52 to -18.6
-20.61 score on a scale
Interval -23.34 to -17.87
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 5
-23.05 score on a scale
Interval -26.29 to -19.81
-24.54 score on a scale
Interval -27.46 to -21.62
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 6
-26.40 score on a scale
Interval -29.98 to -22.83
-28.63 score on a scale
Interval -31.76 to -25.5
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
Day 7
-28.99 score on a scale
Interval -33.54 to -24.44
-27.55 score on a scale
Interval -32.31 to -22.8
Adjusted Mean Change From Baseline in WURSS-21 Total QoL Domain Score
EOT
-25.57 score on a scale
Interval -28.08 to -23.05
-23.54 score on a scale
Interval -25.86 to -21.23

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 1
-0.87 score on a scale
Interval -1.2 to -0.54
-0.96 score on a scale
Interval -1.25 to -0.68
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 2
-1.91 score on a scale
Interval -2.26 to -1.57
-1.77 score on a scale
Interval -2.06 to -1.48
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 3
-2.91 score on a scale
Interval -3.26 to -2.57
-2.78 score on a scale
Interval -3.08 to -2.48
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 4
-3.34 score on a scale
Interval -3.71 to -2.96
-3.46 score on a scale
Interval -3.78 to -3.14
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 5
-3.66 score on a scale
Interval -4.07 to -3.25
-3.78 score on a scale
Interval -4.12 to -3.43
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 6
-4.01 score on a scale
Interval -4.47 to -3.55
-4.44 score on a scale
Interval -4.8 to -4.07
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
Day 7
-4.29 score on a scale
Interval -4.88 to -3.7
-4.54 score on a scale
Interval -5.1 to -3.97
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough
EOT
-3.96 score on a scale
Interval -4.26 to -3.66
-3.92 score on a scale
Interval -4.19 to -3.65

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 1
-0.65 score on a scale
Standard Deviation 1.49
-0.33 score on a scale
Standard Deviation 1.51
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 2
-1.29 score on a scale
Standard Deviation 1.85
-1.02 score on a scale
Standard Deviation 1.70
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 3
-2.05 score on a scale
Standard Deviation 1.93
-1.61 score on a scale
Standard Deviation 1.69
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 4
-2.33 score on a scale
Standard Deviation 1.89
-1.97 score on a scale
Standard Deviation 2.11
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 5
-2.23 score on a scale
Standard Deviation 2.05
-2.29 score on a scale
Standard Deviation 1.67
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 6
-2.33 score on a scale
Standard Deviation 1.88
-2.71 score on a scale
Standard Deviation 1.84
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
Day 7
-2.48 score on a scale
Standard Deviation 1.63
-2.47 score on a scale
Standard Deviation 2.50
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Runny Nose
EOT
-2.80 score on a scale
Standard Deviation 1.93
-2.60 score on a scale
Standard Deviation 1.89

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 1
-0.58 score on a scale
Standard Deviation 1.63
-0.22 score on a scale
Standard Deviation 1.37
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 2
-1.25 score on a scale
Standard Deviation 1.88
-1.01 score on a scale
Standard Deviation 1.79
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 3
-1.94 score on a scale
Standard Deviation 2.08
-1.65 score on a scale
Standard Deviation 1.95
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 4
-2.09 score on a scale
Standard Deviation 2.03
-1.84 score on a scale
Standard Deviation 2.10
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 5
-2.15 score on a scale
Standard Deviation 2.13
-2.02 score on a scale
Standard Deviation 2.04
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 6
-2.15 score on a scale
Standard Deviation 2.12
-2.82 score on a scale
Standard Deviation 1.64
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
Day 7
-2.14 score on a scale
Standard Deviation 2.13
-2.67 score on a scale
Standard Deviation 2.16
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Plugged Nose
EOT
-2.52 score on a scale
Standard Deviation 2.28
-2.52 score on a scale
Standard Deviation 1.93

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 1
-0.65 score on a scale
Standard Deviation 1.61
-0.59 score on a scale
Standard Deviation 1.53
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 2
-1.43 score on a scale
Standard Deviation 1.92
-1.09 score on a scale
Standard Deviation 1.77
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 3
-1.88 score on a scale
Standard Deviation 2.03
-1.60 score on a scale
Standard Deviation 1.80
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 4
-2.10 score on a scale
Standard Deviation 2.18
-1.83 score on a scale
Standard Deviation 1.80
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 5
-2.06 score on a scale
Standard Deviation 2.10
-1.75 score on a scale
Standard Deviation 1.64
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 6
-2.05 score on a scale
Standard Deviation 1.78
-2.04 score on a scale
Standard Deviation 1.51
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
Day 7
-1.86 score on a scale
Standard Deviation 1.65
-2.00 score on a scale
Standard Deviation 1.96
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sneezing
EOT
-2.64 score on a scale
Standard Deviation 1.93
-2.24 score on a scale
Standard Deviation 1.95

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 1
-0.84 score on a scale
Standard Deviation 1.68
-0.70 score on a scale
Standard Deviation 1.57
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 2
-1.65 score on a scale
Standard Deviation 1.91
-1.53 score on a scale
Standard Deviation 1.61
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 3
-2.23 score on a scale
Standard Deviation 2.08
-2.26 score on a scale
Standard Deviation 1.78
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 4
-2.36 score on a scale
Standard Deviation 2.04
-2.86 score on a scale
Standard Deviation 1.87
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 5
-2.42 score on a scale
Standard Deviation 2.13
-2.70 score on a scale
Standard Deviation 1.76
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 6
-2.72 score on a scale
Standard Deviation 1.92
-3.56 score on a scale
Standard Deviation 1.63
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
Day 7
-2.48 score on a scale
Standard Deviation 1.99
-3.27 score on a scale
Standard Deviation 1.67
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Sore Throat
EOT
-2.96 score on a scale
Standard Deviation 1.98
-3.23 score on a scale
Standard Deviation 1.87

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 1
-0.72 score on a scale
Standard Deviation 1.64
-1.10 score on a scale
Standard Deviation 1.44
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 2
-1.49 score on a scale
Standard Deviation 1.99
-1.91 score on a scale
Standard Deviation 1.87
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 3
-2.28 score on a scale
Standard Deviation 2.27
-2.61 score on a scale
Standard Deviation 1.79
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 4
-2.42 score on a scale
Standard Deviation 2.23
-3.11 score on a scale
Standard Deviation 1.69
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 5
-2.62 score on a scale
Standard Deviation 2.20
-3.04 score on a scale
Standard Deviation 1.77
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 6
-2.85 score on a scale
Standard Deviation 2.01
-3.73 score on a scale
Standard Deviation 1.54
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
Day 7
-3.05 score on a scale
Standard Deviation 2.09
-3.80 score on a scale
Standard Deviation 1.66
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Scratchy Throat
EOT
-3.06 score on a scale
Standard Deviation 1.99
-3.58 score on a scale
Standard Deviation 1.82

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms include runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 1
-0.73 score on a scale
Standard Deviation 1.48
-0.54 score on a scale
Standard Deviation 1.58
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 2
-1.66 score on a scale
Standard Deviation 1.78
-1.03 score on a scale
Standard Deviation 1.59
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 3
-2.28 score on a scale
Standard Deviation 2.06
-1.91 score on a scale
Standard Deviation 1.59
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 4
-2.38 score on a scale
Standard Deviation 2.11
-2.41 score on a scale
Standard Deviation 1.86
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 5
-2.67 score on a scale
Standard Deviation 2.10
-2.62 score on a scale
Standard Deviation 2.06
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 6
-2.72 score on a scale
Standard Deviation 2.08
-3.22 score on a scale
Standard Deviation 1.96
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
Day 7
-2.67 score on a scale
Standard Deviation 1.80
-3.07 score on a scale
Standard Deviation 2.09
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Hoarseness
EOT
-3.15 score on a scale
Standard Deviation 2.00
-2.95 score on a scale
Standard Deviation 2.06

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 1
-0.54 score on a scale
Standard Deviation 1.68
-0.41 score on a scale
Standard Deviation 1.78
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 2
-1.31 score on a scale
Standard Deviation 1.98
-0.92 score on a scale
Standard Deviation 1.77
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 3
-1.95 score on a scale
Standard Deviation 2.31
-1.81 score on a scale
Standard Deviation 1.71
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 4
-2.17 score on a scale
Standard Deviation 2.37
-1.94 score on a scale
Standard Deviation 2.29
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 5
-2.21 score on a scale
Standard Deviation 2.25
-2.32 score on a scale
Standard Deviation 2.07
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 6
-2.51 score on a scale
Standard Deviation 1.99
-3.00 score on a scale
Standard Deviation 1.75
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
Day 7
-2.38 score on a scale
Standard Deviation 2.42
-3.00 score on a scale
Standard Deviation 2.45
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Head Congestion
EOT
-2.91 score on a scale
Standard Deviation 2.06
-2.67 score on a scale
Standard Deviation 2.09

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 1
-0.55 score on a scale
Standard Deviation 1.57
-0.49 score on a scale
Standard Deviation 1.66
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 2
-1.30 score on a scale
Standard Deviation 1.88
-1.01 score on a scale
Standard Deviation 1.65
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 3
-1.95 score on a scale
Standard Deviation 1.78
-1.98 score on a scale
Standard Deviation 1.87
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 4
-2.13 score on a scale
Standard Deviation 1.76
-2.16 score on a scale
Standard Deviation 2.00
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 5
-2.33 score on a scale
Standard Deviation 2.02
-2.34 score on a scale
Standard Deviation 1.71
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 6
-2.31 score on a scale
Standard Deviation 1.76
-2.87 score on a scale
Standard Deviation 1.44
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
Day 7
-2.33 score on a scale
Standard Deviation 1.65
-3.07 score on a scale
Standard Deviation 2.19
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Chest Congestion
EOT
-2.75 score on a scale
Standard Deviation 1.94
-2.82 score on a scale
Standard Deviation 1.92

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The individual symptoms included runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion and feeling tired. Participants rated each of the 10 individual symptom domain questions and the responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptom and 7=Severe. Thus, the minimum and maximum score for each symptom domain question was 0 and 7, where higher scores indicated more negative impact on symptoms. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 1
-0.63 score on a scale
Standard Deviation 1.65
-0.68 score on a scale
Standard Deviation 1.52
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 2
-1.65 score on a scale
Standard Deviation 2.04
-1.42 score on a scale
Standard Deviation 1.64
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 3
-2.69 score on a scale
Standard Deviation 1.95
-2.20 score on a scale
Standard Deviation 1.93
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 4
-2.93 score on a scale
Standard Deviation 2.26
-2.61 score on a scale
Standard Deviation 1.96
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 5
-2.87 score on a scale
Standard Deviation 2.00
-2.95 score on a scale
Standard Deviation 1.80
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 6
-3.49 score on a scale
Standard Deviation 1.96
-3.51 score on a scale
Standard Deviation 1.74
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
Day 7
-2.81 score on a scale
Standard Deviation 1.94
-3.47 score on a scale
Standard Deviation 2.03
Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Feeling Tired
EOT
-3.47 score on a scale
Standard Deviation 2.02
-3.50 score on a scale
Standard Deviation 1.78

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 1
-0.29 score on a scale
Standard Deviation 1.76
-0.34 score on a scale
Standard Deviation 1.67
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 2
-1.11 score on a scale
Standard Deviation 2.02
-0.97 score on a scale
Standard Deviation 1.96
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 3
-1.78 score on a scale
Standard Deviation 1.86
-1.55 score on a scale
Standard Deviation 2.22
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 4
-1.81 score on a scale
Standard Deviation 2.43
-1.97 score on a scale
Standard Deviation 2.26
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 5
-1.90 score on a scale
Standard Deviation 2.31
-1.88 score on a scale
Standard Deviation 2.27
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 6
-2.41 score on a scale
Standard Deviation 2.04
-2.62 score on a scale
Standard Deviation 2.05
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
Day 7
-2.24 score on a scale
Standard Deviation 1.87
-2.13 score on a scale
Standard Deviation 3.50
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Think Clearly
EOT
-2.62 score on a scale
Standard Deviation 1.91
-2.41 score on a scale
Standard Deviation 2.35

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicate more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 1
-0.92 score on a scale
Standard Deviation 2.22
-0.83 score on a scale
Standard Deviation 2.35
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 2
-1.91 score on a scale
Standard Deviation 2.37
-1.57 score on a scale
Standard Deviation 2.40
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 3
-2.58 score on a scale
Standard Deviation 2.40
-2.35 score on a scale
Standard Deviation 2.50
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 4
-2.74 score on a scale
Standard Deviation 2.85
-2.66 score on a scale
Standard Deviation 2.39
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 5
-2.83 score on a scale
Standard Deviation 2.66
-3.09 score on a scale
Standard Deviation 2.10
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 6
-3.10 score on a scale
Standard Deviation 2.82
-3.47 score on a scale
Standard Deviation 2.31
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
Day 7
-2.24 score on a scale
Standard Deviation 2.51
-3.87 score on a scale
Standard Deviation 2.36
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Sleep Well
EOT
-3.63 score on a scale
Standard Deviation 2.34
-3.27 score on a scale
Standard Deviation 2.54

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 1
-0.47 score on a scale
Standard Deviation 1.80
-0.48 score on a scale
Standard Deviation 1.67
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 2
-1.40 score on a scale
Standard Deviation 2.02
-0.92 score on a scale
Standard Deviation 1.88
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 3
-2.27 score on a scale
Standard Deviation 1.88
-1.66 score on a scale
Standard Deviation 1.81
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 4
-2.48 score on a scale
Standard Deviation 2.36
-2.04 score on a scale
Standard Deviation 1.99
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 5
-2.38 score on a scale
Standard Deviation 2.09
-2.21 score on a scale
Standard Deviation 1.98
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 6
-2.41 score on a scale
Standard Deviation 2.02
-2.87 score on a scale
Standard Deviation 1.85
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
Day 7
-1.86 score on a scale
Standard Deviation 2.03
-2.00 score on a scale
Standard Deviation 1.89
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Breathe Easily
EOT
-2.90 score on a scale
Standard Deviation 2.06
-2.52 score on a scale
Standard Deviation 2.11

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 1
-0.43 score on a scale
Standard Deviation 1.80
-0.14 score on a scale
Standard Deviation 1.93
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 2
-1.23 score on a scale
Standard Deviation 1.93
-0.66 score on a scale
Standard Deviation 2.15
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 3
-1.70 score on a scale
Standard Deviation 1.96
-1.29 score on a scale
Standard Deviation 2.11
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 4
-2.00 score on a scale
Standard Deviation 2.37
-1.76 score on a scale
Standard Deviation 2.13
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 5
-1.87 score on a scale
Standard Deviation 2.13
-2.09 score on a scale
Standard Deviation 2.04
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 6
-1.95 score on a scale
Standard Deviation 1.50
-2.60 score on a scale
Standard Deviation 1.84
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
Day 7
-2.10 score on a scale
Standard Deviation 1.61
-2.40 score on a scale
Standard Deviation 2.03
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Walk, Climb Stairs, Exercise
EOT
-2.55 score on a scale
Standard Deviation 2.03
-2.14 score on a scale
Standard Deviation 2.25

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 1
-0.44 score on a scale
Standard Deviation 1.81
-0.23 score on a scale
Standard Deviation 1.52
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 2
-1.46 score on a scale
Standard Deviation 1.83
-0.87 score on a scale
Standard Deviation 1.86
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 3
-2.17 score on a scale
Standard Deviation 1.96
-1.46 score on a scale
Standard Deviation 1.85
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 4
-2.28 score on a scale
Standard Deviation 2.27
-1.84 score on a scale
Standard Deviation 1.84
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 5
-2.13 score on a scale
Standard Deviation 1.85
-2.12 score on a scale
Standard Deviation 1.83
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 6
-2.38 score on a scale
Standard Deviation 1.63
-2.78 score on a scale
Standard Deviation 1.64
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
Day 7
-2.43 score on a scale
Standard Deviation 1.69
-2.80 score on a scale
Standard Deviation 1.52
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Accomplish Daily Activities
EOT
-2.94 score on a scale
Standard Deviation 2.00
-2.56 score on a scale
Standard Deviation 1.93

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 1
-0.35 score on a scale
Standard Deviation 2.22
-0.32 score on a scale
Standard Deviation 1.84
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 2
-1.25 score on a scale
Standard Deviation 2.04
-0.78 score on a scale
Standard Deviation 2.08
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 3
-2.01 score on a scale
Standard Deviation 2.05
-1.46 score on a scale
Standard Deviation 2.00
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 4
-2.06 score on a scale
Standard Deviation 2.53
-1.71 score on a scale
Standard Deviation 2.09
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 5
-2.10 score on a scale
Standard Deviation 2.21
-2.11 score on a scale
Standard Deviation 2.07
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 6
-2.26 score on a scale
Standard Deviation 1.96
-2.47 score on a scale
Standard Deviation 2.07
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
Day 7
-2.33 score on a scale
Standard Deviation 2.73
-2.40 score on a scale
Standard Deviation 2.06
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Outside the Home
EOT
-2.64 score on a scale
Standard Deviation 2.38
-2.51 score on a scale
Standard Deviation 2.28

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 1
-0.29 score on a scale
Standard Deviation 1.72
-0.27 score on a scale
Standard Deviation 1.77
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 2
-1.21 score on a scale
Standard Deviation 1.80
-0.88 score on a scale
Standard Deviation 1.88
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 3
-1.98 score on a scale
Standard Deviation 1.90
-1.40 score on a scale
Standard Deviation 2.00
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 4
-2.01 score on a scale
Standard Deviation 2.34
-1.86 score on a scale
Standard Deviation 1.91
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 5
-2.10 score on a scale
Standard Deviation 2.14
-2.21 score on a scale
Standard Deviation 1.93
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 6
-2.21 score on a scale
Standard Deviation 1.87
-2.78 score on a scale
Standard Deviation 1.92
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
Day 7
-2.29 score on a scale
Standard Deviation 2.19
-2.40 score on a scale
Standard Deviation 1.76
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Work Inside the Home
EOT
-2.65 score on a scale
Standard Deviation 2.07
-2.41 score on a scale
Standard Deviation 2.10

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 1
-0.28 score on a scale
Standard Deviation 2.12
-0.45 score on a scale
Standard Deviation 1.97
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 2
-1.31 score on a scale
Standard Deviation 2.04
-1.12 score on a scale
Standard Deviation 2.07
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 3
-2.16 score on a scale
Standard Deviation 2.07
-1.82 score on a scale
Standard Deviation 2.11
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 4
-2.20 score on a scale
Standard Deviation 2.30
-2.01 score on a scale
Standard Deviation 2.10
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 5
-2.40 score on a scale
Standard Deviation 2.14
-2.43 score on a scale
Standard Deviation 1.85
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 6
-2.36 score on a scale
Standard Deviation 1.98
-3.07 score on a scale
Standard Deviation 1.98
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
Day 7
-2.52 score on a scale
Standard Deviation 1.97
-3.07 score on a scale
Standard Deviation 1.67
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Interact With Others
EOT
-2.88 score on a scale
Standard Deviation 2.15
-2.77 score on a scale
Standard Deviation 2.21

PRIMARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The WURSS was an evaluative illness specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. The QoL domain of WURSS-21 consisted of 9 questions. Participants rated each QoL questions indicating how cold interfered with their ability to perform daily activities, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. Thus, the minimum and maximum possible total scores were 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 1
-0.15 score on a scale
Standard Deviation 2.11
-0.55 score on a scale
Standard Deviation 1.82
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 2
-1.42 score on a scale
Standard Deviation 1.95
-1.05 score on a scale
Standard Deviation 2.07
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 3
-2.30 score on a scale
Standard Deviation 2.02
-1.89 score on a scale
Standard Deviation 2.08
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 4
-2.29 score on a scale
Standard Deviation 2.19
-1.94 score on a scale
Standard Deviation 2.09
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 5
-2.29 score on a scale
Standard Deviation 1.95
-2.61 score on a scale
Standard Deviation 2.15
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 6
-2.46 score on a scale
Standard Deviation 1.92
-3.09 score on a scale
Standard Deviation 2.00
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
Day 7
-2.38 score on a scale
Standard Deviation 1.75
-2.73 score on a scale
Standard Deviation 2.09
Mean Change From Baseline in Each of the WURSS-21 QoL Questions Scores: Live Your Personal Life
EOT
-2.93 score on a scale
Standard Deviation 2.07
-2.76 score on a scale
Standard Deviation 2.30

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 1
-2.51 score on a scale
Standard Deviation 2.15
-2.70 score on a scale
Standard Deviation 1.95
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 2
-3.15 score on a scale
Standard Deviation 2.13
-2.97 score on a scale
Standard Deviation 2.04
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 3
-3.58 score on a scale
Standard Deviation 1.88
-3.49 score on a scale
Standard Deviation 2.01
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 4
-3.99 score on a scale
Standard Deviation 1.94
-3.79 score on a scale
Standard Deviation 1.85
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 5
-3.84 score on a scale
Standard Deviation 2.12
-4.00 score on a scale
Standard Deviation 1.81
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 6
-4.11 score on a scale
Standard Deviation 1.97
-4.40 score on a scale
Standard Deviation 1.86
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
Day 7
-3.57 score on a scale
Standard Deviation 1.99
-4.86 score on a scale
Standard Deviation 2.41
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Social Activities
EOT
-4.29 score on a scale
Standard Deviation 1.90
-4.34 score on a scale
Standard Deviation 2.07

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 2
-2.65 score on a scale
Standard Deviation 2.10
-2.78 score on a scale
Standard Deviation 1.85
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 1
-1.91 score on a scale
Standard Deviation 1.93
-2.03 score on a scale
Standard Deviation 1.94
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 3
-3.19 score on a scale
Standard Deviation 1.87
-3.37 score on a scale
Standard Deviation 2.11
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 4
-3.55 score on a scale
Standard Deviation 2.14
-3.55 score on a scale
Standard Deviation 2.22
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 5
-3.53 score on a scale
Standard Deviation 2.09
-3.68 score on a scale
Standard Deviation 1.93
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 6
-3.55 score on a scale
Standard Deviation 2.13
-4.31 score on a scale
Standard Deviation 1.83
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
Day 7
-3.48 score on a scale
Standard Deviation 2.48
-4.64 score on a scale
Standard Deviation 1.45
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Self-conscious Around People
EOT
-3.97 score on a scale
Standard Deviation 1.86
-4.21 score on a scale
Standard Deviation 2.01

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 1
-2.03 score on a scale
Standard Deviation 2.09
-2.23 score on a scale
Standard Deviation 1.76
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 2
-2.93 score on a scale
Standard Deviation 2.09
-2.96 score on a scale
Standard Deviation 2.08
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 3
-3.44 score on a scale
Standard Deviation 1.98
-3.63 score on a scale
Standard Deviation 2.21
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 4
-3.83 score on a scale
Standard Deviation 2.20
-3.73 score on a scale
Standard Deviation 2.19
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 5
-3.86 score on a scale
Standard Deviation 2.17
-4.09 score on a scale
Standard Deviation 1.95
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 6
-3.89 score on a scale
Standard Deviation 2.20
-4.48 score on a scale
Standard Deviation 2.09
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
Day 7
-3.57 score on a scale
Standard Deviation 2.23
-4.93 score on a scale
Standard Deviation 2.20
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Coughing in Public
EOT
-4.29 score on a scale
Standard Deviation 2.18
-4.64 score on a scale
Standard Deviation 1.93

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 1
-2.86 score on a scale
Standard Deviation 1.88
-3.40 score on a scale
Standard Deviation 2.08
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 2
-3.35 score on a scale
Standard Deviation 1.93
-3.54 score on a scale
Standard Deviation 1.91
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 3
-4.19 score on a scale
Standard Deviation 1.75
-4.27 score on a scale
Standard Deviation 1.91
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 4
-4.35 score on a scale
Standard Deviation 1.99
-4.39 score on a scale
Standard Deviation 1.89
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 5
-4.02 score on a scale
Standard Deviation 2.19
-4.43 score on a scale
Standard Deviation 1.58
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 6
-4.26 score on a scale
Standard Deviation 2.11
-4.90 score on a scale
Standard Deviation 1.82
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
Day 7
-4.33 score on a scale
Standard Deviation 1.80
-5.21 score on a scale
Standard Deviation 1.93
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Falling Asleep
EOT
-4.86 score on a scale
Standard Deviation 1.66
-5.07 score on a scale
Standard Deviation 1.66

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 1
-3.05 score on a scale
Standard Deviation 1.95
-3.51 score on a scale
Standard Deviation 2.06
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 2
-3.40 score on a scale
Standard Deviation 1.92
-3.73 score on a scale
Standard Deviation 2.03
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 3
-4.08 score on a scale
Standard Deviation 1.86
-4.28 score on a scale
Standard Deviation 1.93
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 4
-4.16 score on a scale
Standard Deviation 2.06
-4.40 score on a scale
Standard Deviation 1.92
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 5
-3.92 score on a scale
Standard Deviation 2.09
-4.47 score on a scale
Standard Deviation 1.60
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 6
-4.11 score on a scale
Standard Deviation 2.04
-4.88 score on a scale
Standard Deviation 1.58
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
Day 7
-4.19 score on a scale
Standard Deviation 1.83
-5.00 score on a scale
Standard Deviation 1.66
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Sleeping Through the Night
EOT
-4.91 score on a scale
Standard Deviation 1.64
-5.12 score on a scale
Standard Deviation 1.55

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 1
-2.33 score on a scale
Standard Deviation 2.21
-2.39 score on a scale
Standard Deviation 1.95
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 2
-3.17 score on a scale
Standard Deviation 2.12
-2.75 score on a scale
Standard Deviation 2.00
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 3
-3.70 score on a scale
Standard Deviation 1.94
-3.42 score on a scale
Standard Deviation 1.89
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 4
-4.14 score on a scale
Standard Deviation 2.05
-3.79 score on a scale
Standard Deviation 1.89
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 5
-3.84 score on a scale
Standard Deviation 1.90
-3.83 score on a scale
Standard Deviation 1.41
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 6
-4.11 score on a scale
Standard Deviation 1.96
-4.21 score on a scale
Standard Deviation 1.69
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
Day 7
-3.81 score on a scale
Standard Deviation 1.86
-4.36 score on a scale
Standard Deviation 1.82
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Energy
EOT
-4.53 score on a scale
Standard Deviation 1.73
-4.38 score on a scale
Standard Deviation 1.71

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

QoL factors were assessed using specific questions related to social activities, feeling self-conscious around people, coughing in public, falling asleep, sleeping through the night, energy, and motivation. Participants rated their response to questions on a scale ranging from 0 to 7, where 0= Not at all and 7= Severely. Thus, the minimum and maximum score for each question was 0 and 7 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 1
-2.21 score on a scale
Standard Deviation 2.12
-2.34 score on a scale
Standard Deviation 1.94
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 2
-2.97 score on a scale
Standard Deviation 2.14
-2.52 score on a scale
Standard Deviation 1.94
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 3
-3.50 score on a scale
Standard Deviation 2.10
-3.41 score on a scale
Standard Deviation 1.77
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 4
-3.93 score on a scale
Standard Deviation 2.12
-3.67 score on a scale
Standard Deviation 1.83
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 5
-3.76 score on a scale
Standard Deviation 1.96
-4.02 score on a scale
Standard Deviation 1.35
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 6
-4.00 score on a scale
Standard Deviation 2.00
-4.29 score on a scale
Standard Deviation 1.53
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
Day 7
-3.86 score on a scale
Standard Deviation 2.06
-4.64 score on a scale
Standard Deviation 1.39
Mean Change From Baseline in QoL Factors Score Assessed Using Specific QoL Questions: Motivation
EOT
-4.37 score on a scale
Standard Deviation 1.79
-4.27 score on a scale
Standard Deviation 1.77

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Sleep quality category included 3 individual questions - Sleep well (WURSS-21: Question 13), Falling asleep (QoL: Question 4) and Sleep through the night (QoL: Question 5). Participants rated each question, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total scores was 0 and 21 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 1
-6.85 score on a scale
Standard Deviation 4.60
-7.72 score on a scale
Standard Deviation 4.93
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 2
-8.65 score on a scale
Standard Deviation 5.38
-8.87 score on a scale
Standard Deviation 4.99
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 3
-10.82 score on a scale
Standard Deviation 4.90
-10.90 score on a scale
Standard Deviation 5.03
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 4
-11.25 score on a scale
Standard Deviation 6.15
-11.43 score on a scale
Standard Deviation 4.75
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 5
-10.78 score on a scale
Standard Deviation 6.25
-11.98 score on a scale
Standard Deviation 4.07
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 6
-11.47 score on a scale
Standard Deviation 6.09
-13.17 score on a scale
Standard Deviation 4.62
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
Day 7
-10.76 score on a scale
Standard Deviation 4.91
-14.00 score on a scale
Standard Deviation 5.32
Mean Change From Baseline in Categorized QoL Questions Score: Sleep Quality
EOT
-13.40 score on a scale
Standard Deviation 4.89
-13.43 score on a scale
Standard Deviation 4.82

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Vitality category was assessed using 3 individual questions - Energy (QoL: Question 6), Motivation (QoL: Question 7), and Feel tired (WURSS-21: Question 11). Participants rated each question, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total score was 0 and 21 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 1
-5.12 score on a scale
Standard Deviation 5.00
-5.36 score on a scale
Standard Deviation 4.22
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 2
-7.76 score on a scale
Standard Deviation 5.21
-6.74 score on a scale
Standard Deviation 4.49
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 3
-9.88 score on a scale
Standard Deviation 5.07
-9.04 score on a scale
Standard Deviation 4.53
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 4
-11.00 score on a scale
Standard Deviation 5.80
-10.12 score on a scale
Standard Deviation 4.84
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 5
-10.43 score on a scale
Standard Deviation 5.31
-10.75 score on a scale
Standard Deviation 3.96
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 6
-11.53 score on a scale
Standard Deviation 5.14
-11.95 score on a scale
Standard Deviation 4.42
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
Day 7
-10.48 score on a scale
Standard Deviation 5.27
-12.36 score on a scale
Standard Deviation 4.36
Mean Change From Baseline in Categorized QoL Questions Score: Vitality
EOT
-12.37 score on a scale
Standard Deviation 4.74
-12.15 score on a scale
Standard Deviation 4.45

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Physical Activities were assessed using 3 individual questions - Breathe easily (WURSS-21: Question 14), Walk, climb stairs, exercise (WURSS-21: Question 15) and Accomplish daily activities (WURSS-21: Question 16). Participants rated each question, and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total score was 0 and 21 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 1
-1.35 score on a scale
Standard Deviation 4.56
-0.84 score on a scale
Standard Deviation 4.11
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 2
-4.09 score on a scale
Standard Deviation 4.76
-2.45 score on a scale
Standard Deviation 5.04
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 3
-6.14 score on a scale
Standard Deviation 5.03
-4.41 score on a scale
Standard Deviation 4.89
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 4
-6.75 score on a scale
Standard Deviation 6.37
-5.64 score on a scale
Standard Deviation 5.06
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 5
-6.38 score on a scale
Standard Deviation 5.56
-6.43 score on a scale
Standard Deviation 4.69
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 6
-6.74 score on a scale
Standard Deviation 4.18
-8.24 score on a scale
Standard Deviation 4.24
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
Day 7
-6.38 score on a scale
Standard Deviation 4.24
-7.20 score on a scale
Standard Deviation 4.41
Mean Change From Baseline in Categorized QoL Questions Score: Physical Activities
EOT
-8.39 score on a scale
Standard Deviation 5.37
-7.23 score on a scale
Standard Deviation 5.49

SECONDARY outcome

Timeframe: Baseline and up to Day 7 or EOT

Population: mITT population. Only those participants with data available at the specified timepoint were analyzed. EOT was defined as the day when the participant ceased study involvement because they no longer required relief from their cough/cold symptoms or the participant reached Day 7 (Or their last available questionnaire information).

The QoL factors were categorized into 4 categories - Sleep quality, Vitality, Physical activity and Social activity. Social Activities were assessed using 4 individual questions - Interact with others (WURSS-21: Question 19), Less comfortable in social activities (QoL: Question 1), Self-conscious around others (QoL: Question 2) and Coughing in public (QoL: Question 3). Participants rated each question and the responses were evaluated on a scale ranging from 0 to 7, where 0=Not at all and 7=Severely. The individual question score was added to derive categorized QoL score. Thus, the minimum and maximum possible total score was 0 and 28 respectively, where higher scores indicated more negative impact on QoL. Baseline was defined as Day 0. Change from Baseline was calculated as each post-Baseline value minus Baseline value.

Outcome measures

Outcome measures
Measure
Robitussin Cough Syrup (Daytime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=111 Participants
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 1
-6.70 score on a scale
Standard Deviation 6.05
-7.38 score on a scale
Standard Deviation 5.13
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 2
-9.99 score on a scale
Standard Deviation 6.77
-9.90 score on a scale
Standard Deviation 6.19
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 3
-12.36 score on a scale
Standard Deviation 6.48
-12.34 score on a scale
Standard Deviation 6.80
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 4
-13.57 score on a scale
Standard Deviation 7.43
-13.12 score on a scale
Standard Deviation 6.90
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 5
-13.61 score on a scale
Standard Deviation 7.50
-14.13 score on a scale
Standard Deviation 6.40
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 6
-13.87 score on a scale
Standard Deviation 7.14
-16.21 score on a scale
Standard Deviation 6.84
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
Day 7
-13.14 score on a scale
Standard Deviation 7.86
-17.50 score on a scale
Standard Deviation 7.10
Mean Change From Baseline in Categorized QoL Questions Score: Social Activities
EOT
-15.43 score on a scale
Standard Deviation 6.67
-15.93 score on a scale
Standard Deviation 6.88

Adverse Events

Robitussin Cough Syrup (Daytime)

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Robitussin Cough Syrup (Daytime)
n=115 participants at risk
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)
n=112 participants at risk
Participants were instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurred first.
Gastrointestinal disorders
Diarrhoea
0.87%
1/115 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.
0.00%
0/112 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.
Gastrointestinal disorders
Nausea
0.87%
1/115 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.
0.00%
0/112 • Immediately after a participant was randomized within the trial and until 2 days following the last administration of study product (approximately up to 10 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including an acclimatization product (or medical device). A serious AE (SAE) was a particular category of AE where the adverse outcome was serious.

Additional Information

Haleon Response Center

HALEON

Phone: +441932959500

Results disclosure agreements

  • Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER